Medication info

Empagmet 5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletEmpagliflozin›5mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Orange-yellow, biconvex, oval film-coated tablet
Packaging
10 tablets/box [(10 tablets/PTP X 1)], 60 tablets/box [(10 tablets/PTP X 6)], 60 tablets/bottle
Approval status
Active

MFDS item code 202201383 · Approved 2022.04.04

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The recommended dose is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional blood glucose control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their current doses of empagliflozin and metformin. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take a double dose at one time; if this happens, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Contraindications, item 2)). Elderly Patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

View approved original text

This medication is used as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. Particularly, combination therapy with empagliflozin and metformin is suitable for patients whose blood sugar is not adequately controlled. Additionally, caution is required for patients with cardiovascular diseases due to the risk of cardiovascular events, and professional guidance should be followed. This medication aids in the prevention of complications related to blood sugar control, thereby improving the patient's health.

How to take

Adult dose

The recommended dose is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional blood glucose control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their current doses of empagliflozin and metformin. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take a double dose at one time; if this happens, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Contraindications, item 2)). Elderly Patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication helps to control blood sugar levels. However, a rare side effect known as severe lactic acidosis may occur with its use, necessitating caution. When taken with other diabetes medications, there is a risk of hypoglycemia. It should not be used in patients with moderate to severe renal impairment, acute kidney issues, serious infections, cardiac conditions, or a history of diabetic ketoacidosis. Furthermore, administration should be discontinued and renal function verified before and after the use of iodinated contrast agents. Pregnant or breastfeeding women should not take this medication. Regular monitoring of renal function is necessary during treatment, and immediate consultation with a doctor is required for symptoms of dehydration, severe vomiting, or diarrhea. Hypoglycemic symptoms may occur, so close monitoring of blood sugar levels is essential, especially when used with insulin or sulfonylurea medications. There is a risk of urinary or genital infections; therefore, prompt treatment is necessary if related symptoms arise. Vitamin B12 levels may decrease, so monitoring vitamin levels is advisable during long-term use. Alcohol should be avoided as it can increase the risk of lactic acidosis. If surgery is planned, the medication should be stopped 48 hours prior, and reinitiated only after confirming normal renal function post-surgery. Elderly patients or those at risk of fluid loss must carefully monitor their fluid status and blood pressure while taking this medication. Safety and efficacy in children have not been established; therefore, it is not recommended for individuals under 18 years of age. In case of overdose, immediate medical attention is necessary, and if lactic acidosis is suspected, dialysis may be required. Store this medication out of reach of children and in its original container.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased vitamin B12 and deficiency
  • ketoacidosis
  • lactic acidosis
  • nausea
  • vomiting
  • diarrhea
Show 123 more
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • urticaria
  • erythema multiforme
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • perineal necrosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colon bleeding
  • headache
  • sensory loss
  • orthostatic dizziness
  • dizziness
  • cerebral infarction
  • insomnia
  • anxiety
  • depression
  • sleep disorders
  • otalgia
  • orthostatic vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • diabetes mellitus
  • hyponatremia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • extremity pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal venous occlusion
  • serous retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exercise-induced dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • epistaxis
  • allergic rhinitis
  • skin laceration
  • rib fracture
  • lumbar ligament syndrome
  • angina
  • palpitations
  • Prinzmetal's angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

Orange-yellow, biconvex, oval film-coated tablet

Package unit

10 tablets/box [(10 tablets/PTP X 1)], 60 tablets/box [(10 tablets/PTP X 6)], 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.